NovoCure Limited Form 3 NovoCure / Mukund Paravasthu ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Paravasthu Mukund

(Last)

(First)

(Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE

19087

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2024

3. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Operating Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	3,663	D
Restricted Share Units	154⁽¹⁾	D
Restricted Share Units	826⁽²⁾	D
Restricted Share Units	1,989⁽³⁾	D
Restricted Share Units	1,138⁽⁴⁾	D
Restricted Share Units	2,381⁽⁵⁾	D
Restricted Share Units	18,463⁽⁶⁾	D
Restricted Share Units	15,337⁽⁷⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (Right to buy)	⁽⁸⁾	03/01/2031	Ordinary Shares	3,848	153.09	D
Stock Options (Right to buy)	⁽⁹⁾	03/01/2031	Ordinary Shares	653	153.09	D
Stock Options (Right to buy)	⁽¹⁰⁾	11/01/2031	Ordinary Shares	831	107.73	D
Stock Options (Right to buy)	⁽¹¹⁾	05/02/2032	Ordinary Shares	10,109	83.77	D
Stock Options (Right to buy)	⁽¹²⁾	05/02/2032	Ordinary Shares	148	83.77	D
Stock Options (Right to buy)	⁽¹³⁾	02/29/2032	Ordinary Shares	3,260	80.59	D
Stock Options (Right to buy)	⁽¹⁴⁾	02/29/2032	Ordinary Shares	1,086	80.59	D
Stock Options (Right to buy)	⁽¹⁵⁾	02/27/2033	Ordinary Shares	4,644	76.97	D
Stock Options (Right to buy)	⁽¹⁶⁾	02/27/2033	Ordinary Shares	1,299	76.97	D
Stock Options (Right to buy)	⁽¹⁷⁾	10/31/2032	Ordinary Shares	2,902	73.2	D
Stock Options (Right to buy)	⁽¹⁸⁾	05/04/2030	Ordinary Shares	4,674	64.15	D
Stock Options (Right to buy)	⁽¹⁸⁾	05/04/2030	Ordinary Shares	5,421	64.15	D
Stock Options (Right to buy)	⁽¹⁹⁾	02/26/2034	Ordinary Shares	23,251	16.3	D
Stock Options (Right to buy)	⁽²⁰⁾	02/26/2034	Ordinary Shares	201	16.3	D
Stock Options (Right to buy)	⁽²¹⁾	01/10/2034	Ordinary Shares	7,146	13.54	D
Stock Options (Right to buy)	⁽²²⁾	01/10/2034	Ordinary Shares	21,426	13.54	D

Explanation of Responses:

1. Represents restricted share units that are scheduled to vest on November 2, 2024, subject to the reporting person's continued employment through such date.

2. Represents restricted share units that are scheduled to vest on March 1, 2025, subject to the reporting person's continued employment through such date.

3. Represents restricted share units that are scheduled to vest on May 3, 2025, subject to the reporting person's continued employment through such date.

4. Represents restricted share units that are scheduled to vest in equal installments on November 1, 2024 and 2025, subject to the reporting person's continued employment through such dates.

5. Represents restricted share units that are scheduled to vest in equal installments on February 28, 2025 and 2026, subject to the reporting person's continued employment through such dates.

6. Represents restricted share units that are scheduled to vest in equal installments on January 11, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

7. Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

8. Options to buy 3,848 ordinary shares, 3,376 shares of which are currently exercisable and the remainder will vest on March 2, 2025, subject to the reporting person's continued employment through such date.

9. These stock options will vest on March 2, 2025, subject to the reporting person's continued employment through such date.

10. Options to buy 831 ordinary shares, 416 shares of which are currently exercisable and the remainder will vest in equal installments on each of November 2, 2024 and 2025, subject to the reporting person's continued employment through such dates.

11. Options to buy 10,109 ordinary shares, 5,129 shares of which are currently exercisable and the remainder will vest in equal installments on each of May 3, 2025 and 2026, subject to the reporting person's continued employment through such dates.

12. These stock options will vest on May 3, 2026, subject to the reporting person's continued employment through such date.

13. Options to buy 3,260 ordinary shares, 2,174 shares of which are currently exercisable and the remainder will vest on March 1, 2025, subject to the reporting person's continued employment through such date.

14. Options to buy 1,086 ordinary shares will vest on March 1, 2026, subject to the reporting person's continued employment through such date.

15. Options to buy 4,644 ordinary shares, 1,486 shares of which are currently exercisable and the remainder will vest in equal installments on each of February 28, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

16. These stock options will vest on February 28, 2027, subject to the reporting person's continued employment through such date.

17. Options to buy 2,902 ordinary shares, 726 shares of which are currently exercisable and the remainder will vest in equal installments on each of November 1, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.

18. Currently exercisable.

19. Options to buy 23,251 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

20. These stock options will vest on February 27, 2028, subject to the reporting person's continued employment through such date.

21. Options to buy 7,146 ordinary shares, 2 shares will vest on January 11, 2025, 1 share will vest on January 11, 2027 and the remaining shares will vest on January 11, 2028, subject to the reporting person's continued employment through such dates.

22. Options to buy 21,426 ordinary shares will vest in equal installments on each of January 11, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

Remarks:

	Steven Robbins, as attorney in fact for Paravasthu, Mukund	10/09/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

NovoCure Limited (NVCR) Form 3NovoCure / Mukund Paravasthu ownership change